Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?
about
A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel DiseasesAssessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative dataDifferential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectivesMaking therapeutic decisions in inflammatory bowel disease: the role of patients.Patient preferences for surgical versus medical therapy for ulcerative colitis.Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland.The role of TNFalpha in ulcerative colitis.Cost-utility analysis of 1-year treatment with adalimumab/standard care and standard care alone for ulcerative colitis in Poland.Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis.Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands.Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota.Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article.Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation.Health utility of patients with Crohn's disease and ulcerative colitis: a systematic review and meta-analysis.Health-Related Utility Weights in a Cohort of Real-World Crohn's Disease Patients.Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis.A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis.Impact of preoperative infliximab use on postoperative infectious complications in ulcerative colitis: the price we have to pay?Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy.Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs.
P2860
Q26775384-5C7285E8-C5E5-49D3-B047-F77F583C563BQ26864906-DE03F400-4EB0-4FEF-99BD-C43B61BA77D8Q28085134-1382C2DF-9C4C-46F9-B925-EC94CD1B1888Q33941262-A227B839-DC69-452E-B51C-F65E1FB56245Q34065549-BB78A79E-DD33-4AC7-AC69-64ECF0502318Q36095921-3D91C0A0-AF56-4D3A-AAEA-3DD53D7B3C4FQ36849148-A1925945-449D-47E1-B9AB-6BB9B8260635Q37322514-43F36971-0FAA-4459-8338-902DB8C3BF86Q37342575-89C4875D-2E29-446F-9FBB-E427852632BBQ37414620-9F479F25-5505-476C-B80B-FFE0467CC2B3Q37470797-E4FE0E9F-F180-48C5-A5EF-6C3F88EE71C4Q38056526-3EADD062-2AE9-4E4C-925D-7B3A581F1DD9Q38613850-30A227C0-5E43-4A5D-8983-95908B7D778AQ38836219-6A7E2451-35C0-43E9-BB1B-3AA560EF522BQ38963456-05B150D6-B6CE-4354-8941-16C3378AC0D2Q39895230-B8CB8F68-259D-4996-AF45-E9D80CF42D9BQ39920100-C410D3E7-EFC8-42C4-90CF-17BB4D8AFA88Q47278775-099A9B74-60C6-4263-8089-48440442FC7AQ47888476-70A26DCA-EE85-4A77-9C7B-0C65E8BF2FADQ50194896-73C7CD5C-573F-4D7E-8904-CD9D8502A874Q50215048-C0B020FA-AB17-4D41-90AA-7FF00C9FBB21Q54518973-B772E66C-D817-4767-B9C7-1DB92C2A4834
P2860
Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Do patient preferences influen ...... refractory ulcerative colitis?
@ast
Do patient preferences influen ...... refractory ulcerative colitis?
@en
type
label
Do patient preferences influen ...... refractory ulcerative colitis?
@ast
Do patient preferences influen ...... refractory ulcerative colitis?
@en
prefLabel
Do patient preferences influen ...... refractory ulcerative colitis?
@ast
Do patient preferences influen ...... refractory ulcerative colitis?
@en
P2093
P1476
Do patient preferences influen ...... refractory ulcerative colitis?
@en
P2093
Dawn T Provenzale
Eugene Foley
Fabio Cominelli
Jane Onken
Kristen O Arseneau
Stephen J Bickston
P304
P356
10.1016/J.CGH.2006.05.003
P407
P577
2006-07-10T00:00:00Z